| __timestamp | Apellis Pharmaceuticals, Inc. | Vertex Pharmaceuticals Incorporated |
|---|---|---|
| Wednesday, January 1, 2014 | 8379522 | 855506000 |
| Thursday, January 1, 2015 | 13730311 | 996170000 |
| Friday, January 1, 2016 | 22978599 | 1047690000 |
| Sunday, January 1, 2017 | 40303878 | 1324625000 |
| Monday, January 1, 2018 | 105285576 | 1416476000 |
| Tuesday, January 1, 2019 | 220968770 | 1754540000 |
| Wednesday, January 1, 2020 | 299921000 | 1829537000 |
| Friday, January 1, 2021 | 420869000 | 3051100000 |
| Saturday, January 1, 2022 | 387236000 | 2540300000 |
| Sunday, January 1, 2023 | 354387000 | 3162900000 |
| Monday, January 1, 2024 | 3630300000 |
Unveiling the hidden dimensions of data
In the competitive world of pharmaceuticals, innovation is key. Over the past decade, Vertex Pharmaceuticals Incorporated has consistently outpaced Apellis Pharmaceuticals, Inc. in research and development (R&D) spending. From 2014 to 2023, Vertex's R&D expenses grew by an impressive 270%, peaking at over $3.16 billion in 2023. In contrast, Apellis saw a significant increase of 4,130% in the same period, yet their R&D spending reached only $420 million at its highest in 2021.
Vertex's commitment to innovation is evident, with R&D expenses averaging nearly $1.8 billion annually, compared to Apellis's $187 million. This substantial investment has positioned Vertex as a leader in the industry, driving advancements in treatments and therapies. As the pharmaceutical landscape evolves, the disparity in R&D spending highlights the strategic priorities of these two companies, with Vertex clearly prioritizing innovation at a larger scale.
Analyzing R&D Budgets: Merck & Co., Inc. vs Apellis Pharmaceuticals, Inc.
Research and Development Investment: Vertex Pharmaceuticals Incorporated vs Regeneron Pharmaceuticals, Inc.
R&D Insights: How Vertex Pharmaceuticals Incorporated and Viatris Inc. Allocate Funds
Who Prioritizes Innovation? R&D Spending Compared for Vertex Pharmaceuticals Incorporated and Exelixis, Inc.
Research and Development Expenses Breakdown: Vertex Pharmaceuticals Incorporated vs Viking Therapeutics, Inc.
Vertex Pharmaceuticals Incorporated vs Catalyst Pharmaceuticals, Inc.: Strategic Focus on R&D Spending
Vertex Pharmaceuticals Incorporated vs Ligand Pharmaceuticals Incorporated: Strategic Focus on R&D Spending
R&D Spending Showdown: Intra-Cellular Therapies, Inc. vs Apellis Pharmaceuticals, Inc.
Who Prioritizes Innovation? R&D Spending Compared for Madrigal Pharmaceuticals, Inc. and Apellis Pharmaceuticals, Inc.
R&D Spending Showdown: Apellis Pharmaceuticals, Inc. vs Arrowhead Pharmaceuticals, Inc.
Research and Development Investment: Apellis Pharmaceuticals, Inc. vs Celldex Therapeutics, Inc.
Who Prioritizes Innovation? R&D Spending Compared for Apellis Pharmaceuticals, Inc. and Xencor, Inc.